Human Genome starts HGS-ETR1 trial in advanced multiple myeloma

By Elaine Rigoli

Tampa, Fla., July 20 - Human Genome Sciences, Inc. has started dosing patients in a randomized phase 2 clinical trial of HGS-ETR1 (mapatumumab) in combination with bortezomib (Velcade) in advanced multiple myeloma.

The company said the primary objective of the study is to evaluate disease response to HGS- ETR1 in combination with bortezomib, versus bortezomib alone, in patients with relapsed or refractory multiple myeloma.

About 100 patients will be enrolled in the United States and Canada and randomized into two treatment groups, with one treatment group receiving the combination of HGS-ETR1 and bortezomib, and the other treatment group receiving bortezomib alone.

Secondary objectives are to evaluate safety and tolerability, and to determine plasma concentrations of HGS-ETR1 for use in a population pharmacokinetic analysis.

Human Genome has completed three phase 2 clinical trials of HGS-ETR1 to evaluate its potential as a single agent for the treatment of specific cancers, including non-Hodgkin's lymphoma, non-small lung cancer and colorectal cancer.

Human Genome, based in Rockville, Md., develops drugs with a focus on protein and antibodies.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.